Present Advances and Future Perspectives of Molecular Targeted Therapy for Osteosarcoma

Osteosarcoma (OS) is a bone cancer mostly occurring in pediatric population. Current treatment regime of surgery and intensive chemotherapy could cure about 60%–75% patients with primary osteosarcoma, however only 15% to 30% can be cured when pulmonary metastasis or relapse has taken place. Hence, n...

Descripción completa

Detalles Bibliográficos
Autores principales: Shaikh, Atik Badshah, Li, Fangfei, Li, Min, He, Bing, He, Xiaojuan, Chen, Guofen, Guo, Baosheng, Li, Defang, Jiang, Feng, Dang, Lei, Zheng, Shaowei, Liang, Chao, Liu, Jin, Lu, Cheng, Liu, Biao, Lu, Jun, Wang, Luyao, Lu, Aiping, Zhang, Ge
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2016
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4848962/
https://www.ncbi.nlm.nih.gov/pubmed/27058531
http://dx.doi.org/10.3390/ijms17040506
Descripción
Sumario:Osteosarcoma (OS) is a bone cancer mostly occurring in pediatric population. Current treatment regime of surgery and intensive chemotherapy could cure about 60%–75% patients with primary osteosarcoma, however only 15% to 30% can be cured when pulmonary metastasis or relapse has taken place. Hence, novel precise OS-targeting therapies are being developed with the hope of addressing this issue. This review summarizes the current development of molecular mechanisms and targets for osteosarcoma. Therapies that target these mechanisms with updated information on clinical trials are also reviewed. Meanwhile, we further discuss novel therapeutic targets and OS-targeting drug delivery systems. In conclusion, a full insight in OS pathogenesis and OS-targeting strategies would help us explore novel targeted therapies for metastatic osteosarcoma.

Ejemplares similares